<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935818</url>
  </required_header>
  <id_info>
    <org_study_id>09-003598</org_study_id>
    <secondary_id>09-002459</secondary_id>
    <secondary_id>1R01CA138417</secondary_id>
    <nct_id>NCT00935818</nct_id>
  </id_info>
  <brief_title>Varenicline and Bupropion for Smoking Cessation</brief_title>
  <acronym>CHANBAN</acronym>
  <official_title>Combination Therapy With Varenicline and Bupropion for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study provides an opportunity to combine varenicline and bupropion SR and capitalize on
      the potential additive benefit. The investigators hypothesize that this will further increase
      long-term (≥ 6 months) smoking abstinence rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smoking is the single most important preventable cause of morbidity, mortality and
      excess health care costs in the United States and accounts for 30% of U.S. cancer deaths.
      Varenicline and bupropion SR (sustained-release) are non nicotine pharmacotherapies
      FDA-indicated for the treatment of tobacco dependence in cigarette smokers. Although
      varenicline has proven greater efficacy than bupropion SR, both medications are associated
      with high end-of-treatment smoking abstinence rates. However, almost two-thirds of smokers
      treated with varenicline report smoking at 6 months. Because varenicline and bupropion SR
      have different mechanisms of action and different neuropharmacologic targets, combination
      pharmacotherapy with these agents may increase long-term smoking abstinence rates above what
      is observed with single-agent therapy. In our recent pilot study of combination therapy with
      varenicline and bupropion SR, we observed treatment to be well-tolerated with 7-day point
      prevalence smoking abstinence rates of 71% (95% CI: 54-85%) at 3 months and 58% (95% CI:
      41-74%) at 6 months. Determining the efficacy of combination therapy compared to single-agent
      therapy has immediate and important clinical implications. In this study, we will conduct a
      randomized, multicenter, controlled clinical trial evaluating the efficacy of combination
      therapy with varenicline and bupropion SR compared to varenicline and placebo in 506
      cigarette smokers at the Mayo Clinic in Rochester, MN, and the University of Minnesota in
      Minneapolis, MN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers.</measure>
    <time_frame>3 months</time_frame>
    <description>Prolonged smoking abstinence is defined as no smoking, not even a puff, in the last 7 days, and a negative response to the question &quot;Since 2 weeks after your target quit date, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Point Prevalence Abstinence at 3 Months.</measure>
    <time_frame>3 months</time_frame>
    <description>biochemically confirmed 7-day point prevalence abstinence defined as no smoking, not even a puff, in the previous 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolonged Smoking Abstinence Rates at 26 Weeks in Cigarettes Smokers.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Gain From Baseline to 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Weight change from baseline to three months in those who met criteria for prolonged abstinence at the 3 month visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Point Prevalence Abstinence at 6 Months.</measure>
    <time_frame>6 months</time_frame>
    <description>Biochemically confirmed abstinence as no smoking, even a puff, for the prior 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged Abstinence at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Point Prevalence Abstinence at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Biochemically confirmed abstinence defined as no smoking, not even a puff, in the last 7 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">506</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>varenicline and buproprion SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>varenicline and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>varenicline - 1 mg bid for 12 weeks</description>
    <arm_group_label>varenicline and buproprion SR</arm_group_label>
    <arm_group_label>varenicline and placebo</arm_group_label>
    <other_name>chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for 12 weeks</description>
    <arm_group_label>varenicline and placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion SR</intervention_name>
    <description>bupropion sr - 150 mg bid for 12 weeks</description>
    <arm_group_label>varenicline and buproprion SR</arm_group_label>
    <other_name>wellbutrin SR</other_name>
    <other_name>zyban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years of age;

          2. Subject has provide written informed consent;

          3. Subject is smoking greater than or equal to 10 cigarettes per day for at least 6
             months;

        3) Subject is able to complete all study visits 4) Subject is in good health as determined
        by the investigator 5) Subject has the ability to participate fully in all aspects of the
        study and keep scheduled appointments 6) Subject is motivated to stop smoking.

        Exclusion Criteria:

        Female and were pregnant, lactating or likely to become pregnant during the trial and not
        able nor willing to use contraception or had:

          1. an unstable medical condition;

          2. another household member participating in the study;

          3. bupropion or varenicline allergy;

          4. current use (previous 30 days) of a tobacco dependence treatment and unable or
             unwilling to discontinue use;

          5. an unstable medical condition or unstable angina, myocardial infarction, or coronary
             angioplasty (past 3 months) or an untreated cardiac dysrhythmia;

          6. a history of renal failure or were on renal dialysis;

          7. a history of seizures;

          8. as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale), current
             non-specific suicidal thoughts or lifetime history of a suicidal attempt (defined as
             &quot;potentially self-injurious act committed with at least some wish to die, as a result
             of act&quot;);

          9. a history of closed head trauma associated with &gt; 30 minutes of loss of consciousness,
             amnesia, skull fracture, subdural hematoma, or brain contusion;

         10. a history or psychosis, bipolar disorder, bulimia or anorexia nervosa;

         11. current moderate or severe depression as assessed by a score of ≥ 20 on the Beck
             Depression Inventory, Second Edition (BDI-II) 10;

         12. active substance abuse other than nicotine;

         13. current (past 14 days) use of an antipsychotic, monoamine oxidase inhibitors, or drugs
             known to interact with bupropion SR;

         14. a recent dose change of their antidepressant (within last 3 months);

         15. untreated hypertension or baseline systolic blood pressure &gt; 180 or diastolic &gt; 100;

         16. current treatment with another investigational drug for tobacco dependence (previous
             30 days); or

         17. current use of bupropion or varenicline (previous 30 days).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Ebbet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorothy Hatsukami, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Skemp Hospital</name>
      <address>
        <city>LaCrosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA. 2014 Jan 8;311(2):155-63. doi: 10.1001/jama.2013.283185.</citation>
    <PMID>24399554</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <results_first_submitted>March 21, 2014</results_first_submitted>
  <results_first_submitted_qc>March 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2014</results_first_posted>
  <last_update_submitted>April 25, 2014</last_update_submitted>
  <last_update_submitted_qc>April 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jon Ebbert</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>nicotine</keyword>
  <keyword>tobacco</keyword>
  <keyword>dependence</keyword>
  <keyword>cessation</keyword>
  <keyword>abstinence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was between October 2009 and April 2012. Volunteers from local communities of Rochester, MN, Minneapolis, MN and LaCrosse, WI, were recruited using newspaper classified ads, radio, TV, internet ads, print ads in magazines, word of mouth, and volunteer wait lists.</recruitment_details>
      <pre_assignment_details>Study subjects who consented, were screened for entry criteria, and asked to return for a physical exam and medical history. If eligible and still interested, the volunteer was asked to return to the baseline visit at which time they would receive the study medication assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline and Buproprion SR</title>
          <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Varenicline and Placebo</title>
          <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Medication Phase</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Smokers from the local community who smoked 10 cigarettes or more per day for the 6 months prior to study entry.</population>
      <group_list>
        <group group_id="B1">
          <title>Varenicline and Buproprion SR</title>
          <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Varenicline and Placebo</title>
          <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="257"/>
            <count group_id="B3" value="506"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="12.2"/>
                    <measurement group_id="B2" value="41.9" spread="12.7"/>
                    <measurement group_id="B3" value="42.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, non-hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smoking rate</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="7.3"/>
                    <measurement group_id="B2" value="19.7" spread="7.9"/>
                    <measurement group_id="B3" value="19.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers.</title>
        <description>Prolonged smoking abstinence is defined as no smoking, not even a puff, in the last 7 days, and a negative response to the question “Since 2 weeks after your target quit date, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?”</description>
        <time_frame>3 months</time_frame>
        <population>intention-to-treat (all randomized subjects included)</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline and Buproprion SR</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Varenicline and Placebo</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers.</title>
          <description>Prolonged smoking abstinence is defined as no smoking, not even a puff, in the last 7 days, and a negative response to the question “Since 2 weeks after your target quit date, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?”</description>
          <population>intention-to-treat (all randomized subjects included)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression with covariate included for study site.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolonged Smoking Abstinence Rates at 26 Weeks in Cigarettes Smokers.</title>
        <time_frame>6 months</time_frame>
        <population>intention to treat - all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline and Buproprion SR</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Varenicline and Placebo</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Smoking Abstinence Rates at 26 Weeks in Cigarettes Smokers.</title>
          <population>intention to treat - all subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic Regression - adjusting for study site</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Gain From Baseline to 3 Months</title>
        <description>Weight change from baseline to three months in those who met criteria for prolonged abstinence at the 3 month visit</description>
        <time_frame>3 months</time_frame>
        <population>analysis was restricted to subjects who had weight measured at the 3 month visit and were classified as meeting criteria for prolonged abstinence</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline and Buproprion SR</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Varenicline and Placebo</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Gain From Baseline to 3 Months</title>
          <description>Weight change from baseline to three months in those who met criteria for prolonged abstinence at the 3 month visit</description>
          <population>analysis was restricted to subjects who had weight measured at the 3 month visit and were classified as meeting criteria for prolonged abstinence</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="3.4"/>
                    <measurement group_id="O2" value="2.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence Abstinence at 3 Months.</title>
        <description>biochemically confirmed 7-day point prevalence abstinence defined as no smoking, not even a puff, in the previous 7 days.</description>
        <time_frame>3 months</time_frame>
        <population>intent to treat - all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline and Buproprion SR</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Varenicline and Placebo</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Abstinence at 3 Months.</title>
          <description>biochemically confirmed 7-day point prevalence abstinence defined as no smoking, not even a puff, in the previous 7 days.</description>
          <population>intent to treat - all subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression adjusted for study site</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point Prevalence Abstinence at 6 Months.</title>
        <description>Biochemically confirmed abstinence as no smoking, even a puff, for the prior 7 days.</description>
        <time_frame>6 months</time_frame>
        <population>Intention to treat - all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline and Buproprion SR</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Varenicline and Placebo</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Abstinence at 6 Months.</title>
          <description>Biochemically confirmed abstinence as no smoking, even a puff, for the prior 7 days.</description>
          <population>Intention to treat - all subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic Regression adjusting for study site</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolonged Abstinence at 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>intention to treat - all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline and Buproprion SR</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Varenicline and Placebo</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Abstinence at 12 Months</title>
          <population>intention to treat - all subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic Regression - adjusting for study site</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point Prevalence Abstinence at 12 Months</title>
        <description>Biochemically confirmed abstinence defined as no smoking, not even a puff, in the last 7 days</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline and Buproprion SR</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Varenicline and Placebo</title>
            <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Abstinence at 12 Months</title>
          <description>Biochemically confirmed abstinence defined as no smoking, not even a puff, in the last 7 days</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic Regression - adjusting for site</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Varenicline and Buproprion SR</title>
          <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Varenicline and Placebo</title>
          <description>Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <description>new diagnosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>death due to complications from human immunodeficiency virus 6 months after the study drug was discontinued</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>trauma</sub_title>
                <description>sustained trauma during a motor vehicle collision</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>food poisining</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>attempted suicide</sub_title>
                <description>9 months after the study drug was discontinued</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>dispepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>flatulance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>difficulty concentrating</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>mood disturbance</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depressive symptoms</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jon Ebbert</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-4736</phone>
      <email>ebbert.jon@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

